Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis.

Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, Yeh EA, Bykova O, Wassmer E, Tardieu M, Kornberg A, Ghezzi A; International Pediatric Multiple Sclerosis Study Group.

Mult Scler. 2012 Jan;18(1):116-27. doi: 10.1177/1352458511430704. Epub 2011 Dec 6.

PMID:
22146610
2.

International Pediatric MS Study Group Clinical Trials Summit: meeting report.

Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E.

Neurology. 2013 Mar 19;80(12):1161-8. doi: 10.1212/WNL.0b013e318288694e.

3.

Treatment of pediatric multiple sclerosis and variants.

Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, Tenembaum S; International Pediatric MS Study Group.

Neurology. 2007 Apr 17;68(16 Suppl 2):S54-65. Review.

PMID:
17438239
4.

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.

Fox EJ, Rhoades RW.

Curr Opin Neurol. 2012 Feb;25 Suppl:S11-9. doi: 10.1097/01.wco.0000413320.94715.e9. Review.

PMID:
22398660
5.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group.

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.

Pharmacologic management of insomnia in children and adolescents: consensus statement.

Mindell JA, Emslie G, Blumer J, Genel M, Glaze D, Ivanenko A, Johnson K, Rosen C, Steinberg F, Roth T, Banas B.

Pediatrics. 2006 Jun;117(6):e1223-32.

PMID:
16740821
8.

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.

Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C; QUASIMS Study Group.

J Neurol. 2007 Jan;254(1):67-77. Epub 2007 Feb 1.

PMID:
17273808
9.
10.

Therapy of multiple sclerosis in children and adolescents.

Tenembaum SN.

Clin Neurol Neurosurg. 2010 Sep;112(7):633-40. doi: 10.1016/j.clineuro.2010.04.015. Epub 2010 May 14. Review.

PMID:
20471159
11.

[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P.

Nervenarzt. 2006 Dec;77(12):1506-18. German.

PMID:
17136556
12.

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.

Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12.

PMID:
21228027
13.

The management of pediatric multiple sclerosis.

Yeh EA, Weinstock-Guttman B.

J Child Neurol. 2012 Nov;27(11):1384-93. doi: 10.1177/0883073812452785. Epub 2012 Aug 21. Review.

PMID:
22914373
14.

Emerging oral therapies in multiple sclerosis.

Conway D, Cohen JA.

Curr Neurol Neurosci Rep. 2010 Sep;10(5):381-8. doi: 10.1007/s11910-010-0125-3.

PMID:
20549393
15.

Control of multiple sclerosis relapses with immunomodulating agents.

Johnson KP.

J Neurol Sci. 2007 May 15;256 Suppl 1:S23-8. Epub 2007 Mar 12. Review.

PMID:
17350652
16.
17.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
18.

A practical approach to immunomodulatory therapy for multiple sclerosis.

Burks JS.

Phys Med Rehabil Clin N Am. 2005 May;16(2):449-66, ix. Review.

PMID:
15893681
19.

Oral laquinimod therapy in relapsing multiple sclerosis.

Preiningerova J.

Expert Opin Investig Drugs. 2009 Jul;18(7):985-9. doi: 10.1517/13543780903044944. Review.

PMID:
19527103
20.

Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.

Stauch C, Reiber H, Rauchenzauner M, Strasak A, Pohl D, Hanefeld F, Gärtner J, Rostásy KM.

Mult Scler. 2011 Mar;17(3):327-34. doi: 10.1177/1352458510388543. Epub 2010 Dec 1.

PMID:
21123302

Supplemental Content

Support Center